Preclinical safety profile of trastuzumab emtansine (T-DM1): mechanism of action of its cytotoxic component retained with improved tolerability.

Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa

Poon, Kirsten Achilles; Flagella, Kelly; Beyer, Joseph; Tibbitts, Jay; Kaur, Surinder; Saad, Ola; Yi, Joo-Hee; Girish, Sandhya; Dybdal, Noel; Reynolds, Theresa.

Affiliation

Poon KA; Genentech, Inc., South San Francisco, CA, USA. Electronic address: achilles.kirsten@gene.com.

Toxicol Appl Pharmacol ; 273(2): 298-313, 2013 Dec 01.

Article in En | MEDLINE | ID: mdl-24035823

Subject(s)

Antibodies, Monoclonal, Humanized/toxicity; Antineoplastic Agents/toxicity; Blood Platelets/drug effects; Cytotoxins/toxicity; Maytansine/analogs & derivatives; Ado-Trastuzumab Emtansine; Animals; Antibodies, Monoclonal, Humanized/adverse effects; Antineoplastic Agents/adverse effects; Blood Platelets/metabolism; Blood Platelets/pathology; Body Weight/drug effects; Body Weight/physiology; Cytotoxins/adverse effects; Drug Evaluation, Preclinical/methods; Female; Humans; Macaca fascicularis; Male; Maytansine/adverse effects; Maytansine/toxicity; Random Allocation; Rats; Rats, Sprague-Dawley; Trastuzumab

Key words

Ado-trastuzumab emtansine; Antibody-drug conjugates; Breast cancer; HER2; T-DM1; Toxicology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Blood Platelets / Cytotoxins / Antibodies, Monoclonal, Humanized / Maytansine / Antineoplastic Agents Type of study: Clinical_trials Limits: Animals / Female / Humans / Male Language: En Journal: Toxicol Appl Pharmacol Year: 2013 Type: Article

Fulltext

XML

PubMed Links

Search on Google